HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 304 | 383 | 79.4% | |
| HF 4 | 2012 | 347 | 420 | 82.6% | |
| HF 4 | 2013 | 361 | 414 | 87.2% | |
| HF004 | 2014 | 180 | 196 | 91.8% | |
| HF004 | 2015 | 215 | 231 | 93.1% | |
| HF004 | 2016 | 201 | 221 | 91.0% | |
| HF004 | 2017 | 215 | 228 | 94.3% | |
| HF004 | 2018 | 226 | 246 | 91.9% | |
| HF004 | 2019 | 249 | 282 | 88.3% | |
| HF004 | 2020 | 255 | 278 | 91.7% | |
| HF006 | 2021 | 351 | 412 | 85.2% | |
| HF006 | 2022 | 403 | 421 | 95.7% | |
| HF006 | 2023 | 504 | 520 | 96.9% |
